Stem Cell Injection in Cancer Survivors

The University of Texas Health Science Center, Houston46 enrolled

Overview

The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC). The secondary purpose of this study is to obtain preliminary evidence for therapeutic efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV dysfunction secondary to AIC.

This phase I, randomized, placebo-controlled, trial will evaluate the safety and feasibility of allo-MSCs administered by transendocardial injection in thirty-seven subjects with anthracycline-induced cardiomyopathy (AIC). The first six subjects received allo-MSC therapy (open label) and were assessed for safety and feasibility of the study procedures. Following 1 month data review of each of the six subjects by the National Heart, Lung, and Blood Institute Gene and Cell Therapy Data Safety Monitoring Board; this was followed by a randomized, double-blind clinical trial enrolling thirty-one subjects. These subjects were randomized 1:1 to receive allo-MSCs or placebo. All subjects underwent cardiac catheterization and study product administration using the NOGA Myostar catheter injection system. Subjects are being followed at 1 day, 1 week, 1 month, 6 months, and 12 months post study product injection. All endpoints are assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days, respectively, after the day of study product injection (Day 0). For the purpose of the safety evaluations and endpoint analysis, the Investigators will utilize an "intention-to-treat" study population. In addition, because this phase I study is the first cell therapy study in this population, at 12 months available standard-of-care medical records for cancer surveillance will be reviewed for cancer recurrence.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Cardiomyopathy Due to Anthracyclines

Interventions

Allo-MSCsBIOLOGICAL

20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

PlaceboBIOLOGICAL

20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria To participate, a subject MUST: 1. Be ≥ 18 and \< 80 years of age 2. Be a cancer survivor with diagnosis of AIC 3. Have an LVEF ≤ 45% by cMRI 4. Be in NYHA class II-III 5. Have received the initial diagnosis of AIC at least six months earlier and be on stable, optimally-tolerated therapy with beta-blockers, ACE inhibitors/ARBs, and/or aldosterone antagonists for 3 months, unless contraindicated 6. Have a period of at least two years of clinical cancer-free state\* and low likelihood of recurrence (a five-year risk of recurrence estimated at 30% or less), as determined by an oncologist, based on tumor type, response to therapy, and negative metastatic work-up at the time of diagnosis (\*exceptions to this are carcinoma in situ or fully resected basal and squamous cell cancer of the skin.) 7. Be a candidate for cardiac catheterization Exclusion Criteria To participate, a subject MUST NOT HAVE: 1. A life expectancy \<12 months 2. A CT scan or baseline cardiac MRI showing new tumor or suspicious lymphadenopathy raising concern of malignancy 3. Presence of obstructive CAD as determined via imaging within 5 years prior to study enrollment provided there have been no symptoms or evidence of CAD since the test 4. Had a previous myocardial infarction 5. A history of radiation therapy AND evidence of constrictive physiology and/or evidence of other patterns of non-ischemic cardiomyopathy on cardiac MRI (e.g., amyloidosis, sarcoidosis, hemochromatosis, pure radiation-induced cardiomyopathy, etc.) not consistent with AIC being the dominant etiology of heart failure 6. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe valvular (any valve) insufficiency/regurgitation within 12 months of consent. 7. Aortic stenosis with valve area ≤ 1.5cm2 8. A history of LV reduction surgery or cardiomyoplasty 9. Evidence of cardiogenic shock 10. A history of ischemic or hemorrhagic stroke within 90 days of baseline testing 11. Liver dysfunction during baseline testing, as evidenced by enzymes (e.g., AST, ALT, alkaline phosphatase) greater than 3 times upper limit of normal 12. Diabetes with poorly controlled blood glucose levels (HbA1c \> 8.5%) 13. An underlying autoimmune disorder or current immunosuppressive therapy (e.g., chronic corticosteroid, rheumatologic or immune modulating therapy) or likelihood of use of immunosuppressive therapy during participation in the trial (medications will be considered on a case by case basis) 14. A baseline eGFR \<35 ml/min/1.73m2 15. A contrast allergy that cannot adequately be managed by premedication 16. Received gene or cell-based therapy from any source within the previous 12 months 17. A hematologic abnormality during baseline testing as evidenced by hemoglobin \< 9 g/dl; hematocrit \< 30%; absolute neutrophil count \< 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values \< 100,000/ul 18. Evidence of active systemic infection at time of study product delivery 19. HIV and/or active HBV or HCV 20. Coagulopathy (INR \> 1.5) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors) (see Section 6.4 re: injection procedure and anticoagulation therapy) Note: Subjects who cannot be withdrawn from anticoagulation will be excluded. 21. Presence of LV thrombus 22. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions: * manufactured before the year 2000 * leads implanted \< 6 weeks prior to consent * non-transvenous epicardial or abandoned leads * subcutaneous ICDs * leadless pacemakers * any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated 23. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded) 24. A cardiac resynchronization therapy (CRT) device implanted \< 3 months prior to consent 25. Other MRI contraindications (e.g. patient body habitus incompatible with MRI) 26. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent 27. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent 28. A history of drug abuse (use of illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months 29. Cognitive or language barriers that prohibit obtaining informed consent or any study elements (interpreter permitted) 30. Participation (currently or within the previous 30 days) in a cardiac related investigational therapeutic (including stem cell based therapies) or device trial 31. Pregnancy, lactation, plans to become pregnant in the next 12 months, or is unwilling to use acceptable forms of birth control during study participation 32. Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up

Locations (7)

Stanford University School of Medicine

Stanford, California, United States

University of Florida-Department of Medicine

Gainesville, Florida, United States

University of Miami-Interdiciplinary Stem Cell Institute

Miami, Florida, United States

Indiana Center for Vascular Biology and Medicine

Indianapolis, Indiana, United States

Outcomes

Primary Outcomes

Proportion of Major Adverse Cardiac Events (MACE)

Proportion of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization).

Time frame: Baseline to 12 months

Proportion of Other Significant Clinical Events

Proportion of other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, pericardial tamponade, infectious myocarditis, hypersensitivity reaction, neoplasm, and/or other potential deleterious late effects.

Time frame: Baseline to 12 months

Subjects With Events Precluding Their Receipt of Product

Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product.

Time frame: Randomization to SPI

Subjects Who Receive Less Than 20 Injections During SPI

Number and percent of subjects who receive less than 20 injections during SPI

Time frame: During SPI procedure

Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)

Number and percent of subjects who did not receive the study product (either 100 million cells or placebo)

Time frame: During SPI procedure

Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable

Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure.

Time frame: Baseline to 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

Change in left ventricular ejection fraction as assessed via cardiac MRI.

Time frame: Baseline to 12 months

Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory

The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). If there is no interaction between change over time and treatment a single calculated value is the slope (the change per six months) from the model. If there is an interaction, the p-value for interaction is presented along with two calculated values representing the slope (the change per six months) for each treatment arm from the model.

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Global Strain (HARP MRI)

Change in global circumferential strain as assessed via cardiac MRI

Time frame: Baseline to 12 months

Change From Baseline in Global Strain (HARP MRI)-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Regional Strain (HARP MRI)

Change in regional longitudinal strain as assessed via cardiac MRI

Time frame: Baseline to 12 months

Change From Baseline in Regional Strain (HARP MRI)-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)

Change in left ventricular end diastolic volume index as measured via cardiac MRI

Time frame: Baseline to 12 months

Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)

Change in left ventricular end systolic volume index as assessed via cardiac MRI

Time frame: Baseline to 12 months

Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Left Ventricular Sphericity Index

Change in Left Ventricular Sphericity Index as assessed by cardiac MRI. Sphericity index is the ratio of the long and short axis measurements of the left ventricle.

Time frame: Baseline to 12 months

Change From Baseline in Left Ventricular Sphericity Index-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Area of Injury

Change in the scar percent (scar mass normalized to left ventricular mass) as assessed via cardiac MRI.

Time frame: Baseline to 12 months

Change From Baseline in Area of Injury-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Exercise Tolerance (Six Minute Walk Test)

Change in the distance walked (in meters) as measured by the six minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 min). The average distance of the two walk tests will be used for analysis.

Time frame: Baseline to 12 months

Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory

Change in the distance walked (in feet) as measured by the six minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 min). The average distance of the two walk tests will be used for analysis. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). If there is no interaction between change over time and treatment a single calculated value is the slope (the change per six months) from the model. If there is an interaction, the p-value for interaction is presented along with two calculated values representing the slope (the change per six months) for each treatment arm from the model.

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score

Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire. Minimum and maximum scores for scale are 0 and 105 respectively. Lower scores indicative of better outcome.

Time frame: Baseline to 12 months

Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw

Time frame: Baseline to 12 months

Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory

Time frame: Assessed as a trajectory (baseline, 6 months, and 12 months)

Cumulative Days Alive and Out of Hospital for Heart Failure

Days alive and out of hospital for heart failure during the study evaluation period. Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit (i.e., 395 days).

Time frame: Baseline to End of 12 Month Visit Window (i.e. 395 days after intervention)